News Headlines Article

CalPERS puts weight behind opposing biosimilar medication notification bill
Sacramento Business Journal

California’s giant pension fund weighed in on biosimilar medications Wednesday, suggesting the stakes are high before they are even approved for sale. The Affordable Care Act calls for an abbreviated pathway for biological products demonstrated to be “biosimilar to” or “interchangeable with” a product approved by the Food and Drug Administration. But to date, the FDA has yet to approve one.